Why did you only focus on asthma? Did you check on pneumonia numbers? I also think you're making some dodgy assumptions of RAP's pricing model. I'd imagine it would more be a license charge where its $x amount per diagnosis rather than a flat fee of $20 for the app.
- Forums
- ASX - By Stock
- RAP
- Ann: Positive Results from Australian Adult Clinical Studies
Ann: Positive Results from Australian Adult Clinical Studies, page-46
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)